Intarcia Dkt No. ALE 058.10 USSN: 09/497,422

J9/497,422 DATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) reby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United	ed
es Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	RECEIVED
gay / Falin //28/2008	CENTRAL FAX CENTER
Date of Transmittal	JAN 28 2008

In Re Application of: Berry, Stephen A., et al.	Confirmation No.: 7482
Serial No.: 09/497,422	Art Unit: 1618
Filing Date: 03 February 2000	Examiner: Fubara, B.M.
Title: STABLE NON-AQUEOUS SINGLE FORMULATIONS UTILIZING SUC	PHASE VISCOUS VEHICLES AND

REVOCATION AND SUBSTITUTE POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned has reviewed all the documents in the chain of title pursuant to 37 C.F.R. §3.73, and to the best of the undersigned's knowledge, Intarcia Therapeutics, Inc., is the assignee of the entire right, title, and interest in this application, specifically: the assignment recorded on 02/03/2000 at Reel/Frame 010596/0960, and the assignment recorded on 12/13/2007 at Reel/Frame 020252/0143.

Intarcia Therapeutics, Inc., hereby revokes all powers of attorney previously given and hereby appoints the following attorney and agent to prosecute this application and to make alterations and amendments therein. Each of the following attorney and agent has full power of substitution and revocation:

Barbara G. McClung (Registration No. 33,113) Gary R. Fabian (Registration No. 33,875)

Intarcia Dkt No. ALE 058.10

USSN: 09/497,422 PATENT

Please direct all future correspondences in connection with this application to:

Customer Number: 000074866

RECEIVED CENTRAL FAX CENTER

JAN 28 2008

Barbara G. McClung, Esq. Vice President, General Counsel and Corporate Secretary Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608

Phone: (510) 652-2600 Fax: (510) 652-2657

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number ALE 058.10) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Dated: \ | [

By:

Barbara G. McClung, Es

Respectfully submitted,

Vice President, General Jounsel and

Corporate Secretary

Intarcia Therapeutics, Inc. Registration No. 33,113

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608

Phone: (510) 652-2600 Fax: (510) 652-2657